HK Stock Market Move | Maiwei Biotech-B (02493) rose more than 7% against the market, and the clinical trial application for 9MW5211 injection was approved by the National Medical Products Administration.
Maiwei Bioscience-B (02493) defied the market by rising more than 7%. As of the time of writing, it had risen by 6.54% to 23.78 Hong Kong dollars, with a turnover of 8,602,500 Hong Kong dollars.
Miwei Biotechnology-B (02493) rose more than 7% against the market. As of the press release, it rose 6.54% to HK$23.78, with a turnover of HK$8.6025 million.
On the news front, Miwei Biotechnology recently announced that its independently developed antibody innovative drug 9MW5211 has officially obtained approval from the National Medical Products Administration to conduct clinical trials for inflammatory bowel disease (IBD). 9MW5211 is the world's first candidate drug to enter clinical trials at its target. Previously, 9MW5211 had been approved by the FDA to conduct clinical trials for IBD in the United States.
It is worth noting that recently at the 2026 ASCO, oral reports on the Phase Ib/II clinical trial results of the innovative drug 9MW2821 targeting Nectin-4ADC in combination with Trastuzumab for the treatment of local advanced or metastatic urothelial carcinoma (la/mUC) patients were presented. The Phase II clinical trial of Trastuzumab in combination with Neoadjuvant Muscle-Invasive Bladder Cancer (MIBC) was presented in poster form. Both studies demonstrated encouraging efficacy and good safety.
Related Articles
Five major standard systems lead the reform. JD INDUSTRIALS (07618) is establishing a solid foundation for digitalization of the industrial supply chain through standardization.
Roadshow Record | China Green (02411): Store operations are steadily improving, with breakthroughs in multi-dimensional formats, and a clear path for long-term development.
HK Stock Market Move | ZJLD(06979) rises by over 6% again. Institutions point out that the company's actual operations are expected to be better than expected, with a net profit margin in the first half of the year reaching close to 20%.
Five major standard systems lead the reform. JD INDUSTRIALS (07618) is establishing a solid foundation for digitalization of the industrial supply chain through standardization.
Roadshow Record | China Green (02411): Store operations are steadily improving, with breakthroughs in multi-dimensional formats, and a clear path for long-term development.
HK Stock Market Move | ZJLD(06979) rises by over 6% again. Institutions point out that the company's actual operations are expected to be better than expected, with a net profit margin in the first half of the year reaching close to 20%.
